A Study To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-03864086 In Healthy Male Subjects

Pfizer

Status and phase: Completed; Phase 1

Conditions: Pain

Treatments: Drug: Placebo; Drug: PF-3864086

Study type: Interventional

Funder types: Industry

Identifiers

NCT00747058

B0361006

Details and patient eligibility

About

The purpose of this study is to determine the safety and tolerability of PF-03864086 in healthy male human volunteers. Determine the pharmacokinetics (calculations of the rate of elimination of PF-03864086 from the body once the compound is ingested).

Enrollment: 28 patients

Sex: Male

Ages: 21 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• healthy male volunteers
• no drug history
• no other medication for 28 pre-dose

Exclusion criteria

• age below 21 years
• age above 55 years

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

28 participants in 2 patient groups, including a placebo group

healthy volunteers

Experimental group

Treatment:

Drug: PF-3864086

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo